Semaglutide and tirzepatide aid weight loss by mimicking gut hormones Ozempic, Wegovy, Mounjaro and Zepbound treat diabetes, support weight loss The weight loss drugs differ in FDA-approved uses ...

Wegovy-maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market. Under Jorgensen's leadership,

Lilly disclosed the initial weight loss results last December. Novo noted that Wegovy is approved to help prevent strokes and heart attacks, saying in a statement that “obesity is about more ...

"Obesity is about more than just a number on a scale," Novo said, adding that Wegovy is the only medicine from a class of digestion-slowing medicines known as GLP-1 agonists approved to prevent ...

The telehealth site will welcome its own small-dose, compounded version of semaglutide, which mimics the function of a GLP-1.